Bitcoin

Crypto markets are currently driven by macro uncertainty and regulatory overhang, not medical news. However, any positive headline that reduces existential fear can spill over into risk assets, especially when sentiment is extremely low. The limited volume and bearish bias mean the effect is likely muted but not zero.

Daily pill daraxonrasib doubles survival time for pancreatic cancer patients, hailed as a breakthrough.

Pancreatic Cancer Breakthrough Daraxonrasib Could Trim Crypto's Risk Premium, Contrarians Say

Pancreatic cancer breakthrough may actually be bearish for crypto as it reduces the 'mortality premium' that drives speculative risk-taking.

Biotech breakthroughs are currently the only bright spot in a risk‑averse macro environment, prompting a modest rotation from safe‑haven assets (like BTC) into high‑growth equities and tokenized health‑care assets. This aligns with the broader trend of capital seeking tangible, near‑term clinical milestones rather than speculative crypto gains.

Phase 1b Lap‑NET1 trial shows that netrin1 antibody NP137 combined with modified FOLFIRINOX improves progression‑free and overall survival in patients with locally advanced pancreatic cancer.

Phase 1b Lap‑NET1 Trial Shows NP137 Boosts Survival in Advanced Pancreatic Cancer

Breakthrough pancreatic‑cancer trial could ignite a fresh wave of tokenized biotech funding, nudging liquidity from BTC into health‑data blockchain protocols.